Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.

Philippe Gabriel Steg,Deepak L Bhatt,Stefan K James,Oliver Darlington,Louise Hoskin,Tabassome Simon,Kim M Fox,Lawrence A Leiter,Shamir R Mehta,Robert A Harrington,Anders Himmelmann,Wilhelm Ridderstråle,Marielle Andersson,Héctor Bueno,Leonardo De Luca,Amarjeet Tank,Carl Mellström,Phil McEwan

European heart journal. Cardiovascular pharmacotherapy（2022）

引用 4|浏览8

暂无评分

摘要

Based on THEMIS results, ticagrelor plus aspirin compared with aspirin alone may be cost-effective in some European countries in patients with T2DM and CAD and no prior myocardial infarction (MI) or stroke. Additionally, ticagrelor is likely to be cost-effective across European countries in patients with a history of PCI.

查看译文

关键词

Coronary artery disease,Cost–effectiveness,Percutaneous coronary intervention,Ticagrelor,Type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要